Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

Hone Health reports that chronic inflammation is a key factor in heart disease risk often overlooked in standard health ...

Dave Coulier has confirmed he is now in remission, and his update has offered relief to fans worldwide. The longtime acotor ...

Lee Ray Sheng may look like he has it all, running a thriving mala chain in Singapore and making Forbes' 30 under 30 list. But for the past few months, the 26-year-old has been battling health issues, ...

The link between nutrition and the immune system does exist, and the state of the intestinal microbiota plays a key role in ...

Immunotherapy for high grade CNS tumors including adult glioblastoma, anaplastic astrocytoma, pediatric high-grade gliomas, ependymoma and medulloblastoma ...

A team led by UCL researchers with Great Ormond Street Hospital (GOSH) and Moorfields Eye Hospital, found B cells—alongside T ...

Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, ...